In-Depth Look at Final FDA Guidance: Bioavailability Studies Submitted in NDAs or INDs
The FDA will host a meeting on 26 October 2022 to provide additional clarity to the final guidance with respect to Agency expectations for submissions containing Bioavailability information for drug